FDA Approves First Drug Treatment of Peanut Allergy for Children

FDA Approves First Drug Treatment of Peanut Allergy for Children

The U.S. Food and Drug Administration approved Aimmune Therapeutics’ Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.  Treatment may be initiated in individuals ages 4 to 17 years with a confirmed diagnosis of peanut allergy and can continue in individuals 4 years of age and older. Patients must always avoid peanuts in the diet. 

FDA Director: A Dangerous Condition

Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research reported, “Peanut allergies impact about 1 million children in the United States and only 1 out of 5 of these children will outgrow their allergy. As there is no cure, allergic individuals must strictly avoid peanut exposure to prevent severe and potentially life-threatening reactions.” He continued, “Even with strict avoidance, inadvertent exposures can and do occur. When used in conjunction with peanut avoidance, Palforzia provides an FDA—approved treatment option to help reduce risk of these allergic reactions in children with peanut allergy.”

The Condition

Peanut allergy is a condition in which the bod...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee